Merck Tumbles on Drug Worries

It will not submit odanacatib for FDA approval this year

   

prescription drugs 300x180 Merck Tumbles on Drug WorriesShares of Merck & Co. (NYSE:MRK) slid almost 3% in Friday morning trading after the company said it will postpone efforts to get Food & Drug Administration (FDA) approval for a drug developed to combat osteoporosis.

Company officials said they would submit odanacatib for regulatory review in 2014. The drug has completed a major late-stage trial, but Merck will wait for data from a extension study of patients in the original trial before it seeks FDA approval to market the medication, Reuters noted.

health630 200x200 Merck Tumbles on Drug Worries
Keryx Shares Soar on Upbeat Kidney Disease Drug Results

Merck also announced fourth-quarter earnings of $1.4 billion. Adjusted EPS came in at 83 cents, topping the 81 cents Wall Street had expected. Sales fell 5% compared to last year, dropping to $11.74 billion for the quarter. However, that exceeded the $11.48 billion forecast by analysts.

Looking forward, Merck estimated 2013 adjusted earnings of between $3.60 and $3.70 a share, less than the $3.82 a share it realized in 2012. Wall Street is looking for a 2013 profit of $3.68 a share.


Article printed from InvestorPlace Media, http://investorplace.com/2013/02/merck-tumbles-on-drug-worries/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.